Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-65 years of age;~* chronic hepatitis C, genotype 1.~Exclusion Criteria:~* decompensated liver disease, or impaired liver function;~* presence or history of non-hepatitis C chronic liver disease;~* HBsAg or HIV infection;~* history of cancer within 5 years, other than localized or in situ cancer of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): None
- Cohort B (Type: EXPERIMENTAL): None
- Cohort C (Type: EXPERIMENTAL): None
- Cohort D (Type: EXPERIMENTAL): None
- Cohort E (Type: EXPERIMENTAL): None
- Cohort F (Type: EXPERIMENTAL): None
- Cohort G (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).